These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 20298151)
1. Carcinogenesis and therapeutic strategies in thyroid cancer. Liu ZM; Wu TT; van Hasselt CA; Chen GG Curr Drug Targets; 2010 Jun; 11(6):716-32. PubMed ID: 20298151 [TBL] [Abstract][Full Text] [Related]
2. Clinical review 158: Beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer. Braga-Basaria M; Ringel MD J Clin Endocrinol Metab; 2003 May; 88(5):1947-60. PubMed ID: 12727938 [TBL] [Abstract][Full Text] [Related]
3. Thyroid cancer molecular signaling pathways and use of targeted therapy. Kundra P; Burman KD Endocrinol Metab Clin North Am; 2007 Sep; 36(3):839-53, viii. PubMed ID: 17673131 [TBL] [Abstract][Full Text] [Related]
4. Novel targeted therapies and immunotherapy for advanced thyroid cancers. Naoum GE; Morkos M; Kim B; Arafat W Mol Cancer; 2018 Feb; 17(1):51. PubMed ID: 29455653 [TBL] [Abstract][Full Text] [Related]
5. Molecular elements of apoptosis-regulating pathways in follicular thyroid cells: mining for novel therapeutic targets in the treatment of thyroid carcinoma. Sarlis NJ; Gourgiotis L Curr Drug Targets Immune Endocr Metabol Disord; 2004 Sep; 4(3):187-98. PubMed ID: 15379722 [TBL] [Abstract][Full Text] [Related]
6. Treatment of recurrent thyroid cancers--is there a light in the horizon? Rovere RK; Awada A Curr Opin Oncol; 2008 May; 20(3):245-8. PubMed ID: 18391621 [TBL] [Abstract][Full Text] [Related]
7. An update on molecular biology of thyroid cancers. Omur O; Baran Y Crit Rev Oncol Hematol; 2014 Jun; 90(3):233-52. PubMed ID: 24405857 [TBL] [Abstract][Full Text] [Related]
8. New therapeutic advances in the management of progressive thyroid cancer. Woyach JA; Shah MH Endocr Relat Cancer; 2009 Sep; 16(3):715-31. PubMed ID: 19218279 [TBL] [Abstract][Full Text] [Related]
13. Signaling Pathways in Thyroid Cancer. Jin S; Yang YT; Bao W Vitam Horm; 2018; 106():501-515. PubMed ID: 29407446 [TBL] [Abstract][Full Text] [Related]
14. Emerging therapies for thyroid carcinoma. Walsh S; Prichard R; Hill AD Surgeon; 2012 Feb; 10(1):53-8. PubMed ID: 22233555 [TBL] [Abstract][Full Text] [Related]
15. Multi-targeted approach in the treatment of thyroid cancer. Zarebczan B; Chen H Minerva Chir; 2010 Feb; 65(1):59-69. PubMed ID: 20212418 [TBL] [Abstract][Full Text] [Related]
16. Alternative therapeutic approaches in the treatment of primary and secondary dedifferentiated and medullary thyroid carcinoma. Biermann K; Biersack HJ; Sabet A; Janzen V Semin Nucl Med; 2011 Mar; 41(2):139-48. PubMed ID: 21272687 [TBL] [Abstract][Full Text] [Related]
17. Lenvatinib: Role in thyroid cancer and other solid tumors. Cabanillas ME; Habra MA Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514 [TBL] [Abstract][Full Text] [Related]
18. Combinatorial Therapies in Thyroid Cancer: An Overview of Preclinical and Clinical Progresses. Laetitia G; Sven S; Fabrice J Cells; 2020 Mar; 9(4):. PubMed ID: 32235612 [TBL] [Abstract][Full Text] [Related]
19. Role of NF-kappaB in thyroid cancer. Pacifico F; Leonardi A Mol Cell Endocrinol; 2010 May; 321(1):29-35. PubMed ID: 19879919 [TBL] [Abstract][Full Text] [Related]
20. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations. Smith N; Nucera C J Clin Endocrinol Metab; 2015 Jan; 100(1):35-42. PubMed ID: 25347569 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]